Elon Musk had a rocket to launch when Covid-19 shut down the U.S. economy in March.
The billionaires area exploration endeavor, SpaceX, was preparing to blast a crewed spacecraft into the sky in May and wanted to stay on schedule. That indicated finding a way to keep facilities safely open and limit the spread of Covid-19, an obstacle when tests remained in short supply.
To keep an eye on the occurrence of the infection among SpaceX employees nationwide, Mr. Musk and the rocket companys leading medical executive worked with physicians and scholastic researchers to build an antibody-testing program. More than 4,000 SpaceX employees offered for monthly blood tests.
Today the group published its findings, which suggest that a certain threshold of antibodies may offer individuals lasting security against the virus. Mr. Musk is noted as a co-author of the peer-reviewed research study, which appears in the journal Nature Communications.
“People can have antibodies, however it doesnt suggest they are going to be immune” to Covid-19, said Galit Alter, a co-author of the study who is a member of the Ragon Institute of MGH, MIT and Harvard. Individuals who experienced less, milder Covid-19 signs created less antibodies and were for that reason less most likely to meet the limit for longer-term immunity, the study discovered.